Diabetic Neuropathy Market Size, Share & Industry Analysis, By Disease Type (Peripheral, Autonomic, Proximal, and Focal), By Drug Class (Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory, and others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Diabetic Neuropathy  Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Diabetic Neuropathy  market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Diabetic Neuropathy  market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Diabetic Neuropathy  Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Diabetic Neuropathy  Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Diabetic Neuropathy  Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled
Introduction of new products by Eli Lilly and Company and Pfizer Inc. to Boost the Company Share
The key players dominating the diabetic neuropathy market are Eli Lilly and Company and Pfizer Inc. owing to an increase in R&D activities. This is influencing major players of the market to expand its product portfolio across the globe. Hence, the diverse product portfolio by key players is tending to generate revenue for the company. In terms of revenue, Eli Lilly and Company holds the dominance attributed to its blockbuster products such as Cymbalta and Prozac. The significant upscale of the product across the globe is expected to fuel the growth of the market during the forecast period. Pfizer Inc. is considered as the prominent market player. Due to its focus on the development of the products like Lyrica and Motrin that are anticipated to drive the growth.

LIST OF KEY COMPANIES PROFILED:

  
Abbott
  
Eli Lilly and Company
  
Pfizer.Inc
  
F. Hoffmann-La Roche Ltd
  
GlaxoSmithKline plc.
  
Janssen Pharmaceuticals, Inc.
  
Lupin Pharmaceuticals, Inc.
  
Astellas Pharma US, Inc.
  
Others

KEY INDUSTRY DEVELOPMENTS:

April 2019 “Daiichi Sankyo launched Tarlige tablets whose generic name being microgabalin bestilate drug to treat patients suffering with peripheral diabetic neuropathy pain in Japan.

October 2018 -Ionis Pharmaceuticals and Akcea Therapeutics together have launched phase III clinical trial AKCEA-TTR-L to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis.

REPORT COVERAGE

The diabetic neuropathy market report provides a detailed analysis of the market and focuses on key features such as leading companies, drug class, and type. Besides this, the report provides key insights into the market trends and highlights key industry developments such as mergers, acquisitions, and collaborations, new product launches, prevalence of diabetic neuropathy, pipeline analysis.  In addition to this, the report also focuses on the major driving factors and restraints that are inducing the market growth during forecast period.

Report Scope & Segmentation

 Segmentation

By Disease Type

  
Peripheral
  
Autonomic
  
Proximal
  
Focal

By Drug Class

  
Non-Steroidal Anti-Inflammatory Drugs
  
Opioid
  
Anti-Depressants
  
Anti-Seizure
  
Others

By Distribution Channel

  
Hospitals Pharmacies
  
Retail Pharmacies & Stores
  
Online Pharmacies

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America)
  
Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)